mifepristone has been researched along with Cancer of Ovary in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 11 (32.35) | 24.3611 |
| 2020's | 5 (14.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Du, X; Eksterowicz, J; Fantin, VR; Huang, E; Huang, T; Jackson, E; Jahchan, N; Kawai, H; McGee, LR; Medina, JC; Rew, Y; Sun, D; Sutimantanapi, D; Waszczuk, J; Yan, X; Ye, Q; Zavorotinskaya, T; Zhou, H; Zhu, L | 1 |
| Gu, Y; Liu, J; Zhang, Y | 1 |
| Pan, Y; Shi, H; Wu, T | 1 |
| Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y | 1 |
| Hajek, RA; Li, X; Liu, J; Liu, Y; Niu, N; Peng, G; Sood, AK; Westin, S; Yao, J; Zhang, X | 1 |
| Bernaczyk, P; Bidzinski, M; Chrusciel, M; Chrusciel, P; Huhtaniemi, IT; Ponikwicka-Tyszko, D; Rahman, NA; Scheinin, M; Stelmaszewska, J; Szamatowicz, J; Sztachelska, M; Wolczynski, S | 1 |
| Bast, RC; Cheon, DJ; Cho, CH; Coffey, DM; DeMayo, FJ; Emerson, RE; Fernández, FM; Godwin, AK; Hawkins, SM; Karpf, AR; Kim, J; Kim, O; Kwon, SY; Lydon, JP; Miller, KD; Nephew, KP; Park, EY; Quilliam, LA; Shin, S; Shin, YH; Sood, AK; Widschwendter, M | 1 |
| Lyu, Y; Shang, L; Wang, Y | 1 |
| Baker, GM; Conzen, SD; Fleming, GF; Kocherginsky, M; Lengyel, E; Skor, MN; Stringer-Reasor, EM | 1 |
| da Silva, SV; Freitas, VM; Lima, MA | 1 |
| Callegari, EA; Chien, J; Drappeau, DD; Eyster, KM; Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Knapp, JR; Pan, B; Srinivasan, R; Telleria, CM; Terpstra, EJ; Wang, X; Zhang, L | 1 |
| Chen, H; Chen, J; Jia, L; Li, T; Liu, J; Liu, W; Wang, J; Zheng, N | 1 |
| Liu, GY; Mi, RR; Qi, J; Qu, QX | 1 |
| Liu, Y; Wang, LL | 1 |
| Freeburg, EM; Goyeneche, AA; Telleria, CM | 1 |
| Brady, WE; Hoffman, JS; Mannel, RS; Rocereto, TF; Rotmensch, J; Shahin, MS; Small, L | 1 |
| Goyeneche, AA; Seidel, EE; Telleria, CM | 1 |
| Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Telleria, CM | 1 |
| Brandhagen, BN; Goyeneche, AA; Telleria, CM; Tieszen, CR; Tracy, MS; Ulmer, TM | 1 |
| Qin, TN; Wang, LL | 1 |
| Lu, J; Xia, B | 1 |
| Deng, Y; Liu, Y; Wang, LL | 1 |
| Song, L; Wang, Z; Xu, M | 1 |
| Ji, M; Li, JJ; Li, Q; Zhao, XB | 1 |
| Li, GY; Li, XJ; Lin, TC; Wang, G; Xiao, P; Zheng, WT | 1 |
| Li, GY; Li, XJ; Lin, TC; Shang, HL; Wang, G; Xiao, P; Xie, Y | 1 |
| Bringuier, AF; Daraï, E; Dufournet Etienne, C; Fauvet, R; Feldmann, G; Poncelet, C | 1 |
| Carón, RW; Goyeneche, AA; Telleria, CM | 1 |
| Chien, CH; Hamilton, TC; Wang, FF | 1 |
| Barnea, ER; Rose, FV | 1 |
| Aikins, JA; Paulson, J; Rocereto, TF; Saul, HM | 1 |
| Vastag, B | 1 |
| McDonnel, AC; Murdoch, WJ | 1 |
| Kumasaka, T | 1 |
4 trial(s) available for mifepristone and Cancer of Ovary
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish | 2023 |
Clinical effect of mifepristone on patients with ovarian cancer in pregnancy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Female; Humans; Mifepristone; Neoplasm Staging; Ovarian Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy, High-Risk | 2019 |
A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mifepristone; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2010 |
Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
30 other study(ies) available for mifepristone and Cancer of Ovary
| Article | Year |
|---|---|
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).
Topics: Animals; Drug Discovery; Female; Hormone Antagonists; Humans; Mice; Ovarian Neoplasms; Rats; Receptors, Glucocorticoid; Swine; Swine, Miniature; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Mifepristone inhibited tumor progression by disrupting the stability of PD-L1 by miR-127-3p/VAMP2 in ovarian cancer.
Topics: Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Hormone Antagonists; Humans; MicroRNAs; Mifepristone; Ovarian Neoplasms; Vesicle-Associated Membrane Protein 2 | 2022 |
Distinct clinicopathological features of ovarian endometriosis after long-term exposure to mifepristone.
Topics: Endometriosis; Endometrium; Female; Humans; Ki-67 Antigen; Mifepristone; Ovarian Cysts; Ovarian Neoplasms; Receptors, Estrogen; Retrospective Studies | 2022 |
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.
Topics: Apoptosis; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; Female; Humans; Mifepristone; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyploidy | 2023 |
Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Humans; Immunohistochemistry; Membrane Proteins; Mice; Mice, Transgenic; Mifepristone; Ovarian Neoplasms; Receptors, Progesterone; Transforming Growth Factor beta1 | 2019 |
Targeting progesterone signaling prevents metastatic ovarian cancer.
Topics: Adult; Animals; BRCA1 Protein; Breast; Breast Neoplasms; Cystadenocarcinoma, Serous; Disease Models, Animal; Estradiol; Female; Humans; Mice; Middle Aged; Mifepristone; Mutation; Neoplasms, Experimental; Ovarian Neoplasms; Ovary; Progesterone; Receptors, Progesterone; Salpingo-oophorectomy; Signal Transduction | 2020 |
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; MCF-7 Cells; Mice; Mice, SCID; Mifepristone; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Random Allocation; Receptors, Glucocorticoid; Xenograft Model Antitumor Assays | 2015 |
Progesterone acts via the progesterone receptor to induce adamts proteases in ovarian cancer cells.
Topics: ADAM Proteins; ADAMTS1 Protein; ADAMTS4 Protein; Cell Line, Tumor; Enzyme Induction; Female; Gene Expression; Humans; Mifepristone; Ovarian Neoplasms; Procollagen N-Endopeptidase; Progesterone; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone | 2016 |
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
Topics: Activating Transcription Factor 4; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cinnamates; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mifepristone; Ovarian Neoplasms; Platinum; Proteasome Inhibitors; Protein Biosynthesis; Puromycin; RNA, Messenger; Signal Transduction; Thiourea; Tunicamycin; Unfolded Protein Response | 2016 |
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Topics: Abortifacient Agents; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Chemoprevention; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Peritoneal Neoplasms; Peritoneum; Receptors, CXCR4; Signal Transduction | 2017 |
[Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells].
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Cycle; Cell Line, Tumor; Cisplatin; Disease Models, Animal; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endonucleases; Female; Humans; Mice; Mice, Nude; Mifepristone; MutL Protein Homolog 1; Neoplasm Transplantation; Nuclear Proteins; Ovarian Neoplasms; RNA, Messenger | 2008 |
[Mifepristone modulates glucosylceramide synthase expression and reverse multidrug resistance in ovarian cancer cells].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucosyltransferases; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Death; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Humans; Mifepristone; Ovarian Neoplasms | 2009 |
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytostatic Agents; DNA Fragmentation; Estrenes; Female; Furans; Hormone Antagonists; Humans; Mifepristone; Norpregnadienes; Ovarian Neoplasms | 2012 |
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Proliferation; Cisplatin; DNA, Neoplasm; Female; G1 Phase; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2012 |
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cytostatic Agents; Female; Hormone Antagonists; Humans; Male; Mifepristone; Neoplasm Invasiveness; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Time Factors | 2013 |
[Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism].
Topics: Abortifacient Agents, Steroidal; Antineoplastic Agents; bcl-2-Associated X Protein; Cell Division; Cisplatin; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Mifepristone; Ovarian Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2002 |
[Rapid inhibition of extracellular signal-regulated kinase 1/2 in a human ovarian cancer cell line by dexamethasone].
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Female; Flavonoids; Humans; Mifepristone; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured | 2002 |
Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo.
Topics: Abortifacient Agents, Steroidal; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Mice; Mice, Nude; Mifepristone; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Effects of Dexamethasone on glucocorticoid receptor expression in a human ovarian carcinoma cell line 3AO.
Topics: Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Mifepristone; Ovarian Neoplasms; Receptors, Glucocorticoid; RNA, Messenger; Tumor Cells, Cultured | 2003 |
[Study of effect of mifepristone on apoptosis of human ovarian cancer cell line 3AO].
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Mifepristone; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2003 |
[Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
Topics: Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mifepristone; Ovarian Neoplasms | 2004 |
Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mifepristone; Ovarian Neoplasms | 2005 |
Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3.
Topics: Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gentian Violet; Hormone Antagonists; Humans; Immunoblotting; Indoles; Microscopy, Fluorescence; Mifepristone; Ovarian Neoplasms; Poly(ADP-ribose) Polymerases; Progesterone; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mifepristone; Ovarian Neoplasms; Protein Kinases | 2007 |
Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells.
Topics: Cell Division; Cystadenocarcinoma, Serous; DNA, Antisense; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Mifepristone; Neoplasm Proteins; Ovarian Neoplasms; Proto-Oncogene Mas; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured | 1994 |
Response of human ovarian carcinoma cell lines to antiprogestin mifepristone.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Hormone Antagonists; Humans; Mifepristone; Ovarian Neoplasms; Paclitaxel; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1996 |
Effect of mifepristone approval on research remains to be seen.
Topics: Abortifacient Agents, Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Female; France; Germany; Humans; Male; Mifepristone; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Progesterone; Prostatic Neoplasms; Research Support as Topic; Tamoxifen; United States; United States Food and Drug Administration | 2000 |
High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.
Topics: Adenocarcinoma; Cell Membrane; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Female; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Mifepristone; Neoplasm Invasiveness; Ovarian Neoplasms; Progesterone; Receptors, Progesterone; Testosterone; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 2001 |
[Current topics in hormone therapy].
Topics: Adult; Anovulation; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Estrenes; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Menotropins; Mifepristone; Ovarian Cysts; Ovarian Neoplasms; Ovulation Induction | 1985 |